Ownership and insider activity for Azitra, Inc. (AZTR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S.
Price
| Price | $0.16 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-16 | Salva Francisco D. | C-Conversion | 4,064,050 | |
| 2026-06-16 | Salva Francisco D. | C-Conversion | 500 | |
| 2026-04-20 | Staskey Norm | A-Award | 35,524 | $8K |
| 2026-04-20 | Salva Francisco D. | A-Award | 220,879 | $47K |
| 2026-04-20 | Whitfill Travis | A-Award | 64,300 | $14K |
| 2026-03-18 | Salva Francisco D. | P-Purchase | 4,064,050 | $500K |
| 2026-03-18 | Salva Francisco D. | P-Purchase | 4,064,050 | $500K |
| 2026-03-18 | Salva Francisco D. | P-Purchase | 500 | $62 |
| 2025-12-19 | Whitfill Travis | A-Award | 23,724 | $7K |
| 2025-12-19 | Salva Francisco D. | A-Award | 59,309 | $18K |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $8.0M | $3.5M | $1.8M | $4.6M | $2.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Receivables | $334178 | $266208 | $223474 | $101896 | $141295 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $8.5M | $4.1M | $2.5M | $5.2M | $3.0M |
| Property, Plant & Equipment | $946681 | $2.0M | $1.6M | $1.2M | $962076 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $97693 | $219567 | $210881 | $246420 | $316673 |
| Total Assets | $10.2M | $7.2M | $5.1M | $7.4M | $5.0M |
| Accounts Payable | $717800 | $784687 | $897272 | $490255 | $399356 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.2M | $2.2M | $1.6M | $1.4M | $1.1M |
| Long-term Debt | $992019 | $6.6M | 0 | 0 | 0 |
| Total Liabilities | $36.0M | $43.4M | $2.2M | $1.7M | $1.2M |
| Retained Earnings | -$26.6M | -$37.3M | -$48.6M | -$57.6M | -$68.5M |
| Total Equity | -$25.8M | -$36.3M | $2.9M | $5.7M | $3.8M |
| Total Debt | $992019 | $7.7M | $885947 | $555509 | $422077 |
| Net Debt | -$7.1M | $4.2M | -$910042 | -$4.0M | -$1.6M |
| Working Capital | $7.3M | $1.9M | $932384 | $3.9M | $2.0M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 4.86 |
Profitability
| Return on Equity | -205.45% |
| Return on Invested Capital | -159.45% |
| Return on Assets | -137.65% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ENVB · INDP · JSPR · LIPO · ONCO · REVB · SCNI
Explore sector: Healthcare · Biotechnology
More sections of AZTR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks